Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment ...

Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and ...

A little-known Chinese company has made a drug that beats the world's biggest-selling medicine, said a CNN report on ...

Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This ...

AstraZeneca signed a $1.92 billion deal with China’s CSPC Pharmaceutical Group (CSPC) last year to develop cardiovascular medication, and Merck has a $2 billion agreement with China’s Hansoh ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter ...

Pfizer has partnered with Summit Therapeutics to evaluate ivonescimab, a PD-1/VEGF bispecific antibody, in combination with ...

Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed the world's first "Operation Log-driven Development Technology" for the development of systems that facilitate and ...

(9926) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT ) has entered into a clinical trial collaboration with Pfizer Inc. (NYSE: PFE ...

ADA, a leader in data and AI-driven digital transformation and all-in-one authentication solutions, and IPification, a pioneer in seamless mobile authentication, have announced their strategic ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.